CHANDAN

Chandan Healthcare Share Price

 

 

Start SIP in CHANDAN

Start SIP

Performance

  • Low
  • ₹260
  • High
  • ₹301
  • 52 Week Low
  • ₹140
  • 52 Week High
  • ₹358
  • Open Price₹300
  • Previous Close₹295
  • Volume148,000
  • 50 DMA₹302.80
  • 100 DMA₹287.36
  • 200 DMA₹245.73

Investment Returns

  • Over 1 Month -8.17%
  • Over 3 Month -8.83%
  • Over 6 Month + 34.85%
  • Over 1 Year + 68.14%

Smart Investing Starts Here Start SIP with Chandan Healthcare for Steady Growth!

Invest Now

Chandan Healthcare Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 29.5
  • PEG Ratio
  • -
  • Market Cap Cr
  • 654
  • P/B Ratio
  • 4.7
  • Average True Range
  • 14.41
  • EPS
  • 9.07
  • Dividend Yield
  • 0
  • MACD Signal
  • -2.19
  • RSI
  • 30.55
  • MFI
  • 29.79

Chandan Healthcare Financials

Chandan Healthcare Technicals

EMA & SMA

Current Price
₹267.35
-28 (-9.48%)
pointer
  • Bearish Moving Average 13
  • Bullish Moving Average 3
  • 20 Day
  • ₹301.64
  • 50 Day
  • ₹302.80
  • 100 Day
  • ₹287.36
  • 200 Day
  • ₹245.73

Resistance and Support

276.2 Pivot Speed
  • R3 333.65
  • R2 317.45
  • R1 292.40
  • S1 251.15
  • S2 234.95
  • S3 209.90

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Chandan Diagnostics is a leading healthcare provider with 50+ centers and 500 collection points across Uttar Pradesh, Uttarakhand, and Rajasthan. Offering 3,500+ tests across multiple specialties, it ensures high-quality diagnostics with ISO and NABL-certified labs, cutting-edge automation, and seamless digital access.

Chandan Healthcare Ltd has an operating revenue of Rs. 533.40 Cr. on a trailing 12-month basis. An annual revenue growth of 30% is outstanding, Pre-tax margin of 14% is healthy, ROE of 18% is exceptional. The company has a reasonable debt to equity of 18%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 20% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 17% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 55 which is a POOR score indicating inconsistency in earnings, a RS Rating of 90 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 19 indicates it belongs to a strong industry group of Medical-Outpnt/Hm Care and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Chandan Healthcare Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-14 Quarterly Results
2025-10-10 To consider Fund Raising
2025-05-27 Audited Results

Chandan Healthcare F&O

Chandan Healthcare Shareholding Pattern

49.47%
1.11%
37.07%
12.35%

About Chandan Healthcare

  • NSE Symbol
  • CHANDAN
  • BSE Symbol
  • Chairman & Managing Director
  • Mr. Amar Singh
  • ISIN
  • INE0B2N01016

Similar Stocks to Chandan Healthcare

Chandan Healthcare FAQs

Chandan Healthcare share price is ₹267 As on 18 January, 2026 | 04:54

The Market Cap of Chandan Healthcare is ₹653.7 Cr As on 18 January, 2026 | 04:54

The P/E ratio of Chandan Healthcare is 29.5 As on 18 January, 2026 | 04:54

The PB ratio of Chandan Healthcare is 4.7 As on 18 January, 2026 | 04:54

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23